Dirlotapide: A review of its properties and role in the management of obesity in dogs

  • Wren J
  • Gossellin J
  • Sunderland S
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction. MTP catalyzes the assembly of triglyceride-rich apolipoprotein-B containing lipoproteins to form chylomicrons in the intestinal mucosa and very low-density lipoproteins in the liver. Following oral administration, dirlotapide has in vivo selectivity for intestinal MTP compared with hepatic MTP. In addition to reducing intestinal fat absorption, dirlotapide also reduces food intake in a dose-dependent manner, probably via increased release of peptide YY into the circulation. The decrease in food intake is responsible for the majority of the weight reduction effect. In clinical use, it is recommended to adjust the dose according to the observed weight loss of each individual. The initial dose of 0.05 mg/kg is doubled after 14 days and then adjusted monthly, the maximum permitted daily dose is 1.0 mg/kg, although doses as high as 10 mg/kg have been administered to dogs without severe adverse experience in safety studies. Dirlotapide can be used without necessitating changes to the current feeding or exercise regimens, but it is desirable to monitor the food intake during weight-stabilization to establish revised feeding and exercise routines that will minimize the risk of weight regain post-treatment. The drug offers a novel approach that is applicable in cases where dietary management alone has proved to be unsuccessful. © 2007 Pfizer Inc.

Author-supplied keywords

  • Animals
  • Anti-Obesity Agents
  • Carbamates
  • Dog Diseases
  • Dogs
  • IC50
  • Indoles
  • Obesity
  • abdominal pain
  • abetalipoproteinemia
  • administration & dosage
  • apolipoprotein B
  • article
  • caloric restriction
  • chylomicron
  • defecation urgency
  • dietary intake
  • dirlotapide
  • dose response
  • drug bioavailability
  • drug dose increase
  • drug half life
  • drug structure
  • drug therapy
  • drug withdrawal
  • dual energy X ray absorptiometry
  • exercise
  • fat intake
  • fatty liver
  • feces incontinence
  • feeding
  • flatulence
  • food intake
  • histopathology
  • human
  • intestine cell
  • lipoprotein
  • microsomal triglyceride transfer protein inhibitor
  • nonhuman
  • obesity
  • pathology
  • peptide YY
  • physical chemistry
  • priority journal
  • recommended drug dose
  • spotting
  • steatorrhea
  • stomach emptying
  • tetrahydrolipstatin
  • therapeutic use
  • unclassified drug
  • upregulation
  • vagotomy
  • very low density lipoprotein
  • veterinary
  • vomiting
  • weight reduction

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J A Wren

  • J Gossellin

  • S J Sunderland

  • Wren J.A.

  • Gossellin J.

  • Sunderland S.J.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free